Myriad Genetics Discloses Certain Preliminary Financial Data For Q3, Expects Revenue Of $210M - $212M (Est $209.397M), Despite Divestiture Of EndoPredict Business In Europe - Filing
Portfolio Pulse from Benzinga Newsdesk
Myriad Genetics has disclosed preliminary financial data for Q3, expecting revenue between $210M and $212M, surpassing estimates despite divesting its EndoPredict business in Europe. The company reaffirms its full-year 2024 revenue guidance of $835M to $845M.
October 09, 2024 | 10:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Myriad Genetics expects Q3 revenue of $210M-$212M, exceeding estimates despite divesting EndoPredict. The company reaffirms its full-year 2024 revenue guidance, indicating strong financial performance.
The preliminary Q3 revenue exceeds estimates, which is a positive indicator for the company's financial health. The reaffirmation of full-year guidance suggests confidence in meeting financial targets, likely boosting investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100